Beyond Mice: How Transgenic Rabbits Are Fueling AI Antibody Discovery

SHANGHAI – November 04, 2026 – For decades, the laboratory mouse has been the undisputed workhorse of the global pharmaceutical industry. Yet, as drug developers push into increasingly complex biological territory, the traditional rodent immune system is hitting a wall. Targets like multi-transmembrane proteins and highly conserved epitopes often fail to elicit a useful immune response in mice, leaving critical therapeutic avenues unexplored.

Today, Shanghai Immunocan Biotech Co., Ltd. announced a technical milestone that could redraw the boundaries of preclinical drug discovery. The company has successfully executed the in situ replacement of megabase-scale human immunoglobulin (Ig) gene segments at endogenous loci in rabbits. Utilizing its proprietary MASIRT (Massive-fragment Across Species In situ Replacement Technology) platform, the firm has effectively engineered rabbits that can produce fully human antibodies.

While transgenic animals are not new, the scale and precision of this genetic edit represent a significant leap. More importantly, this development is not merely a biological triumph; it is a strategic maneuver designed to feed the next generation of artificial intelligence models with the diverse, cross-species data required to design superior therapeutics.

Breaking the Rodent Bottleneck

The fundamental challenge in modern antibody discovery is target complexity. Many of the most sought-after pharmaceutical targets—such as G-protein coupled receptors (GPCRs), ion channels, and transporters—are notoriously difficult to drug. Because these proteins are highly conserved across mammalian species, a mouse's immune system often recognizes them as "self" rather than foreign, resulting in a weak or non-existent antibody response.

Rabbits, however, possess a distinct B-cell ontogeny and a uniquely robust immune system. They are capable of generating highly diverse and specific antibodies against epitopes that are either poorly immunogenic in rodents or highly conserved. Historically, the hurdle has been engineering rabbits to produce human antibodies suitable for clinical use without triggering an immune rejection in patients.

Previous attempts at creating humanized rabbits often relied on random integration transgenic approaches. These methods involved microinjecting human gene constructs into animal embryos, a blunt-force technique that often resulted in fragmented gene insertion, unstable immune responses, and poor antibody diversity. While modern tools like CRISPR have simplified basic gene editing, integrating massive DNA segments—spanning millions of base pairs—into the mammalian genome remains a profound hurdle.

The Shanghai-based biotech's MASIRT platform circumvents these legacy issues. Genotypic characterization confirms that the technology enables a targeted, single-step replacement of megabase-scale human immunoglobulin gene segments precisely at the rabbit's endogenous Ig loci. By executing this massive genetic swap in situ, the platform preserves the animal's natural structural organization and regulatory elements. The result is a more stable, naturalistic immune response capable of generating a vast repertoire of fully human antibodies.

"Achieving megabase-scale replacement in non-rodent mammals without disrupting the underlying regulatory architecture is a profound technical hurdle," noted an independent genetic engineering expert specializing in mammalian genome editing. "If the germline transmission and immune characterization hold up, this opens access to a tier of complex pharmaceutical targets that have historically frustrated the industry."

Feeding the Generative AI Engine

Beyond the immediate utility of discovering novel antibodies for hard-to-hit targets, the creation of a humanized rabbit model serves a deeper, perhaps more lucrative, computational purpose. The frontier of drug development is increasingly dominated by artificial intelligence, with generative models promising to design antibodies in silico, predict their developability, and map epitopes with unprecedented speed.

However, these AI models face an acute bottleneck: data starvation. Algorithms are only as good as the data they are trained on, and the current wellspring of biological data is overwhelmingly mouse-centric. Training an AI on a single species limits its ability to understand the full spectrum of sequence-function relationships.

By establishing a cross-species data engine, the company is positioning itself as a vital supplier of high-affinity, diverse biological data. The firm's established humanized mouse platforms—which include models for fully human antibodies, common light-chain antibodies, and heavy-chain-only antibodies—have already generated hundreds of millions of data points.

Integrating the newly unlocked rabbit antibody repertoire into this dataset introduces novel specificities and binding modes. Because rabbit-derived antibodies frequently recognize conserved epitopes shared by human and mouse proteins, this cross-reactivity data is exceptionally valuable for training predictive algorithms on preclinical translatability. In essence, the multi-species experimental data allows AI models to learn from a vastly expanded universe of successful antibody-antigen interactions, thereby de-risking the computational design of future drugs.

"The AI drug discovery space is realizing that compute is no longer the primary constraint; high-quality, diverse biological data is the new oil," observed a biotech venture capital leader focused on AI platforms. "A proprietary engine that can spit out cross-species binding data at scale is exactly what generative models need to move from theoretical design to clinical viability."

The Economics of the Platform Play

The successful engineering of the humanized rabbit also highlights a broader geopolitical and economic shift within the life sciences sector. Founded in 2020, the firm has rapidly moved up the value chain, transitioning from the traditional Chinese biotech model of contract manufacturing and fast-follower drug development to foundational intellectual property creation.

This platform-centric business model is highly scalable and capital-efficient. Rather than bearing the immense cost and clinical risk of developing its own therapeutic pipeline, the company operates as an innovation engine for the broader industry. By offering access to its proprietary transgenic animals and the resulting data, it secures high-margin licensing agreements and milestone payments.

The strategy is already yielding commercial traction. The firm has established partnerships with more than 30 pharmaceutical organizations worldwide, including several multinational corporations. Furthermore, a recent Series A financing round of RMB 250 million (approximately $34.5 million USD) in May 2026, led by Vivo Capital, underscores strong investor confidence in this licensing model. The capital injection is explicitly earmarked for commercializing the rabbit platform and establishing an AI-driven drug screening ecosystem.

This approach insulates the company from the binary success-or-failure nature of clinical trials. Whether a specific partner's drug succeeds or fails, the platform provider continues to generate revenue through upfront licenses and data access fees, effectively taxing the industry's research and development expenditure.

The Road Ahead for Cross-Species Pipelines

While the in situ megabase replacement marks a critical breakthrough, the development of a fully validated commercial platform requires rigorous downstream validation. The company is currently evaluating the integrity, rearrangement, and expression of the introduced human gene segments. Crucially, it must confirm stable germline transmission through breeding and assess the actual discovery performance across diverse, challenging target classes.

Simultaneously, the firm is exploring the expansion of its rabbit models to support heavy-chain-only and multispecific antibody discovery, mirroring the comprehensive suite of tools it currently offers in mice. These specialized formats are increasingly vital for the development of next-generation modalities, such as bispecific T-cell engagers and antibody-drug conjugates.

As biological engineering and computational science become inextricably linked, the ability to generate massive, diverse, and high-fidelity biological datasets will dictate the pace of pharmaceutical innovation. By successfully bridging the genetic gap between mice and rabbits, the industry is not just finding new ways to drug complex proteins; it is actively writing the training manual for the artificial intelligence systems that will design the therapeutics of tomorrow.